Keros Therapeutics (KROS) Stock Price, News & Analysis

Company Overview

Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis. KER-050 is currently being evaluated in multiple clinical trials across North America and Europe. In parallel, Keros is advancing additional preclinical programs that leverage its proprietary platform to address other hematologic and iron-related disorders.

Founded in 2019 as a spin-out from academic research, Keros Therapeutics is headquartered in Boston, Massachusetts, and collaborates with leading research institutions and clinical centers worldwide. The company’s leadership team comprises industry veterans in research and development, clinical operations and regulatory affairs, all focused on translating groundbreaking science into therapies that improve patient outcomes in serious blood diseases.

Key Stats

• Today's Range: $10.43 to $10.92
• 50-Day Range: $9.91 to $12.55
• 52-Week Range: $9.69 to $22.55
• Volume: 400,525 shs
• Average Volume: 228,478 shs
• Market Capitalization: $211.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.40
• Consensus Rating: Hold

Keros Therapeutics Stock Analysis - MarketRank™

Keros Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 258th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Keros Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 3 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Keros Therapeutics has a consensus price target of $20.40, representing about 90.9% upside from its current price of $10.69.

Amount of Analyst Coverage

Keros Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($5.19) to ($5.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Keros Therapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Keros Therapeutics is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Keros Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.89% of the float of Keros Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Keros Therapeutics has a short interest ratio ("days to cover") of 4.54.

Change versus previous month

Short interest in Keros Therapeutics has recently decreased by 11.48%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Keros Therapeutics does not currently pay a dividend.

Dividend Growth

Keros Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.81

News Sentiment

Keros Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Keros Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Keros Therapeutics insiders have sold 311.12% more of their company's stock than they have bought. Specifically, they have bought $21,890.00 in company stock and sold $89,994.00 in company stock.

Percentage Held by Insiders

20.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/19/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KROS
• CIK: 1664710
• Web: www.kerostx.com
• Phone: 617-314-6297
• Fax: N/A
• Employees: 100
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Keros Therapeutics: $20.40
• High Price Target: $27.00
• Low Price Target: $16.00
• Potential Upside/Downside: +90.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $87.01 million
• Net Margins: -256.60%
• Pretax Margin: -272.15%
• Return on Equity: -17.04%
• Return on Assets: -15.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.61
• Quick Ratio: 22.62

Sales & Book Value

• Annual Sales: $244.06 million
• Price / Sales: 0.87
• Cash Flow: $4.65 per share
• Price / Cash Flow: 2.30
• Book Value: $15.51 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 19,790,000
• Free Float: 15,715,000
• Market Cap: $211.46 million
• Optionable: Optionable
• Beta: 0.94